Barclays
TIL icon

Barclays’s Instil Bio TIL Stock Holding History

Barclays’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223 Sell
29
-4,106
-99% -$33.1K ﹤0.01% 5099
2026
Q1 		$34.1K Sell
4,135
-6,010
-59% -$48.8K ﹤0.01% 4442
2025
Q4 		$112K Buy
10,145
+3,995
+65% +$59.1K ﹤0.01% 4549
2025
Q3 		$110K Sell
6,150
-4,250
-41% -$108K ﹤0.01% 4585
2025
Q2 		$217K Sell
10,400
-4,426
-30% -$92.5K ﹤0.01% 4222
2025
Q1 		$257K Buy
14,826
+11,999
+424% +$249K ﹤0.01% 3909
2024
Q4 		$54K Buy
2,827
+2,767
+4,612% +$84.4K ﹤0.01% 4747
2024
Q3 		$4.04K Sell
60
-419
-87% -$9.87K ﹤0.01% 5044
2024
Q2 		$4.93K Hold
479
– – ﹤0.01% 4578
2024
Q1 		$5.17K Buy
+479
New +$5.25K ﹤0.01% 4869
2023
Q4 		– Sell
-17,652
Closed -$151K – 5350
2023
Q3 		$151K Buy
+17,652
New +$178K ﹤0.01% 3416
2023
Q2 		– Sell
-2,217
Closed -$29.3K – 5070
2023
Q1 		$29.3K Buy
2,217
+1,283
+137% +$19K ﹤0.01% 4579
2022
Q4 		$11.8K Buy
934
+786
+531% +$38.8K ﹤0.01% 4893
2022
Q3 		$14K Sell
148
-27
-15% -$3.09K ﹤0.01% 4188
2022
Q2 		$16K Sell
175
-264
-60% -$37.4K ﹤0.01% 4489
2022
Q1 		$95K Buy
+439
New +$103K ﹤0.01% 3808

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $14.6M AUM 63.08% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Barclays's TIL Position: Q2 2026 in Review

Barclays reduced its Instil Bio (TIL) stake by 99% in Q2 2026, selling an estimated $33.1K and leaving 29 shares worth $223. The position accounts for ﹤0.01% of the portfolio, ranked #5099.

Barclays first reported a position in TIL in Q1 2022 and has held it in 16 quarters since. The position peaked at $257K in Q1 2025. 26 funds tracked by Wall St. Rank hold TIL as of Q2 2026.

  • Barclays held 29 shares of Instil Bio worth $223 as of Q2 2026.
  • Barclays sold 4,106 Instil Bio shares in Q2 2026, an estimated $33.1K.
  • Instil Bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5099 holding.
  • Barclays first reported a position in Instil Bio in Q1 2022 and has held it in 16 quarters since.
  • Barclays's Instil Bio position peaked at $257K in Q1 2025.
  • 26 funds tracked by Wall St. Rank held Instil Bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.